000827246 000__ 03145cam\a2200517Ii\4500
000827246 001__ 827246
000827246 005__ 20230306144605.0
000827246 006__ m\\\\\o\\d\\\\\\\\
000827246 007__ cr\cn\nnnunnun
000827246 008__ 180403s2018\\\\sz\\\\\\ob\\\\001\0\eng\d
000827246 019__ $$a1030486105$$a1030607255$$a1030767994$$a1033655328
000827246 020__ $$a9783319679327$$q(electronic book)
000827246 020__ $$a3319679325$$q(electronic book)
000827246 020__ $$z9783319679303
000827246 020__ $$z3319679309
000827246 0247_ $$a10.1007/978-3-319-67932-7$$2doi
000827246 035__ $$aSP(OCoLC)on1030303308
000827246 035__ $$aSP(OCoLC)1030303308$$z(OCoLC)1030486105$$z(OCoLC)1030607255$$z(OCoLC)1030767994$$z(OCoLC)1033655328
000827246 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dGW5XE$$dN$T$$dYDX$$dOCLCF$$dUPM$$dMERER
000827246 049__ $$aISEA
000827246 050_4 $$aRC271.C5
000827246 08204 $$a616.99/4061$$223
000827246 24500 $$aResistance to anti-cancer therapeutics targeting receptor tyrosine kinases and downstream pathways /$$cYosef Yarden, Moshe Elkabets, editors.
000827246 264_1 $$aCham, Switzerland :$$bSpringer,$$c2018.
000827246 300__ $$a1 online resource.
000827246 336__ $$atext$$btxt$$2rdacontent
000827246 337__ $$acomputer$$bc$$2rdamedia
000827246 338__ $$aonline resource$$bcr$$2rdacarrier
000827246 347__ $$atext file$$bPDF$$2rda
000827246 4901_ $$aResistance to targeted anti-cancer therapeutics ;$$vvolume 15
000827246 504__ $$aIncludes bibliographical references and index.
000827246 5050_ $$aResistance of colorectal tumors to anti-EGFR antibodies -- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK -- Mechanisms of action and resistance of trastuzumab in breast cancer -- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis -- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge -- Mechanisms of resistance to PI3K and AKT inhibitors -- Sensitivity and resistance to BH3 mimetics in cancer therapy -- Resistance mechanisms to cyclin-dependent kinase inhibitors -- Resistance to inhibitors of angiogenesis.
000827246 506__ $$aAccess limited to authorized users.
000827246 520__ $$aThis volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
000827246 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 5, 2018).
000827246 650_0 $$aDrug resistance in cancer cells.
000827246 650_0 $$aAntineoplastic agents.
000827246 650_0 $$aCancer$$xChemotherapy.
000827246 7001_ $$aYarden, Y.$$q(Yosef),$$eeditor.
000827246 7001_ $$aElkabets, Moshe,$$eeditor.
000827246 77608 $$iPrint version: $$z9783319679303$$z3319679309$$w(OCoLC)1002128204
000827246 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 15.
000827246 852__ $$bebk
000827246 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-67932-7$$zOnline Access$$91397441.1
000827246 909CO $$ooai:library.usi.edu:827246$$pGLOBAL_SET
000827246 980__ $$aEBOOK
000827246 980__ $$aBIB
000827246 982__ $$aEbook
000827246 983__ $$aOnline
000827246 994__ $$a92$$bISE